Eye Clinicians Can Diagnose and Treat Migraine with Targeted Questions and Stepwise Plan

Migraine lands in eye clinics more often than most ophthalmologists expect. At the American Academy of Ophthalmology's annual meeting in New Orleans in October 2026, neuro-ophthalmologists laid out a practical framework for recognizing and treating headaches that patients bring to their eye doctors first—before they ever see a neurologist or headache specialist.

The numbers tell the story. At an academic medical center, about three-quarters of patients who walk in complaining of a headache actually have migraine. The formal diagnostic criteria are exacting: at least five attacks per month, each lasting four to 72 hours, with specific pain features like one-sided location, throbbing quality, moderate-to-severe intensity, or worsening with activity, plus nausea or sensitivity to both light and sound. But Sam Spiegel, a neuro-ophthalmologist at UCI Health in Orange County, California, showed that ophthalmologists don't need to run through the whole checklist. Three targeted questions—Does this headache stop you from working? Do you feel nauseous? Do you want to close your eyes and dim the lights during an attack?—yield a 93% positive predictive value for migraine when all three answers are yes. That's the kind of efficiency that works in a busy clinic.

Visual aura, the shimmer or blind spot that sometimes precedes migraine, follows its own rules. Vivek Patel, chief of neuro-ophthalmology at UCI Health, explained that true aura builds gradually over at least five minutes, clears within an hour, and arrives before or alongside the headache itself. If the aura comes after the headache starts, that's a warning sign pointing toward something else. The aura itself reflects cortical spreading depression—a wave of electrical activity moving across the visual cortex—and some people experience it without any headache at all. Migraine is the most common neurologic cause of light sensitivity, Patel noted, and he recommended FL-41 tinted lenses, which patients can wear indoors to reduce photophobia.

Treatment starts with the basics and climbs a ladder. Every patient begins with lifestyle management: regular sleep and wake times matter more than total hours, Spiegel said. Protein at each meal, consistent hydration, and 15 minutes daily of heart-rate-raising exercise form the foundation. Over-the-counter magnesium has evidence behind it and can be offered to nearly everyone. For acute attacks, nonsteroidal anti-inflammatory drugs like ibuprofen remain first-line therapy. Triptans come next, with the main caution being cardiovascular disease. Gepants represent another option. The timing matters: treating at the first sign of aura or pain stops more attacks than waiting. But patients need guardrails—limiting headache abortive medication to fewer than 10 days per month prevents medication overuse headache, a trap many fall into.

When attacks are frequent, debilitating, or don't respond to acute treatment, daily preventives enter the picture. Anti-seizure medications, beta blockers, and nortriptyline sit in the middle tier. At the top of the ladder are CGRP-targeted preventive drugs and onabotulinumtoxinA (Botox) for chronic migraine. Here's where the system breaks down: those advanced therapies require prior authorization and support staff that most ophthalmology practices don't have. Headache clinic wait times stretch nine to 12 months. Spiegel urged early referral to specialists while starting patients on lower-rung treatments in the meantime.

Not every headache that looks like migraine is migraine. Trochleitis—inflammation of the superior oblique tendon—causes pain near the inner upper eye socket that worsens with eye movement and touch, without vision loss. Patel noted it responds well to an in-office steroid and anesthetic injection near the trochlea, with oral indomethacin or prednisone as alternatives. Red flags that demand imaging include a new headache after age 50, a change in established headache patterns, papilledema, or cranial nerve palsy. Otherwise, Spiegel said, eye care clinicians should refer without hesitation. "It's your job to make sure that they have the tools they need that can improve their life along the way," he told the room.